Michael Braun: The Work Is Not Finished in Sickle Cell Disease
Michael Braun, U.S. Specialty Care President at Pfizer, shared a post on LinkedIn:
“Sickle cell disease affects millions of people worldwide — and still carries the weight of inequity. For too many, the journey is defined not just by pain and crises, but by delayed diagnoses, limited access to specialized care, and treatment options that haven’t kept pace with the urgency.
On World Sickle Cell Day, I’m thinking about a community that has been asked to wait too long for progress — and what it means to truly show up for them.
For our team at Pfizer, that means continuing to advance our research and education in sickle cell disease, supporting scholarships, helping nonprofit organizations in their mission to ease the burden of travel to care, and listening closely to the people most affected.
Progress is possible, and it’s also necessary. Our work isn’t finished.
To everyone living with sickle cell, caring for someone who is, or fighting for change in this community:
Stay updated with Hemostasis Today.
-
Sep 21, 2026, 20:56George Touma: ApoB Should Be Central to All Lipid Guidlines
-
Sep 21, 2026, 20:55Christopher Robinson: Obstetric Risks Are Seen at the Extremes of Birthweight
-
Sep 21, 2026, 20:54Emicizumab for Refractory GI Bleeding in Myeloma-Associated Acquired VWD – JTH
-
Sep 21, 2026, 20:52Ross Baker: ASH 2026 Guidelines on Iron Deficiency in HMB and Bleeding Disorders
-
Sep 21, 2026, 20:50Rainer Kaiser: Genes and Signalling Pathways Implicated in Procoagulant Platelet Generation
-
Sep 21, 2026, 20:49Natalia Dovlatova: Celebrating Stan Heptinstall and His Legacy in Platelet Science
-
Sep 21, 2026, 20:48Norm Roulet: The Interaction of Pb and SARS-CoV-2 and Its Impact on the Cardiovascular System
-
Sep 21, 2026, 20:45Felix Scholkmann: The Spleen Plays a Key Role in Regulating Platelet Activity
-
Sep 21, 2026, 20:43Claire Pomeroy: Celebrating the 2026 Lasker Awards and Why Medical Research Matters